10-Q: FOXO Technologies Reports Third Quarter 2024 Results, Includes Impact of Recent Acquisitions

FOXO Technologies' third quarter 2024 results reflect the impact of recent acquisitions in the healthcare sector, alongside ongoing developments in its Labs and Life segment.

Summary

• FOXO Technologies reported a net loss attributable to common stockholders of $2.03 million for the three months ended September 30, 2024, compared to a net loss of $4.57 million for the same period in 2023.
• The company's net revenues increased significantly to $1.2 million in Q3 2024, up from $10 in Q3 2023, primarily due to the acquisitions of Myrtle Recovery Centers and Rennova Community Health.
• Operating expenses totaled $2.2 million in Q3 2024, a decrease from $3.5 million in Q3 2023, driven by lower research and development and selling, general and administrative expenses.
• For the nine months ended September 30, 2024, the net loss attributable to common stockholders was $6.67 million, compared to $25.97 million for the same period in 2023.
• The company's total assets increased substantially to $42.7 million as of September 30, 2024, compared to $725,000 as of December 31, 2023, primarily due to the acquisitions.
• The company's total liabilities also increased significantly to $60.2 million as of September 30, 2024, compared to $14.8 million as of December 31, 2023, due to the acquisitions and related debt.
• The company's cash and cash equivalents were $34,000 as of September 30, 2024, compared to $38,000 as of December 31, 2023.

Sentiment

Score: 4

Explanation: The document shows some positive developments with revenue growth due to acquisitions, but the company's weak cash position, high debt, and ongoing losses raise significant concerns. The company's ability to continue as a going concern is also in question.

Positives

• The company's net revenues increased significantly due to the acquisitions of Myrtle and RCHI.
• Operating expenses decreased due to lower research and development and selling, general and administrative expenses.
• The net loss attributable to common stockholders improved compared to the same period in the previous year.
• The company's total assets increased substantially due to the acquisitions.

Negatives

• The company's cash and cash equivalents remain very low at $34,000.
• The company's total liabilities increased significantly due to the acquisitions and related debt.
• The company continues to operate at a loss, with a net loss of $2.03 million for the quarter.
• The company has a working capital deficit of $31.4 million and a total stockholders deficit of $17.5 million.

Risks

• The company's ability to continue as a going concern is dependent on generating revenue, raising additional capital, reducing losses, and improving future cash flows.
• The company is subject to non-compliance notices from the NYSE American due to a stockholders deficit and losses from continuing operations.
• The company's Senior PIK Notes are in default, and the company has not had the financial ability to correct this default.
• The company is subject to various legal proceedings and regulatory matters, including a complaint from holders of the Senior PIK Notes.
• The company's operations are susceptible to risks associated with the healthcare industry, including changes in regulations, reimbursement rates, and competition.
• The company's operations are dependent on the local economies and the surrounding areas in which they operate and are concentrated in Tennessee.

Future Outlook

The company expects the Myrtle and RCHI businesses to be cash flow neutral through the remainder of 2024 and believes it will be able to fund its operations until the second quarter of 2025. The company is also pursuing additional funding through a combination of equity or debt financings and additional strategic acquisitions.

Management Comments

• Management believes there is value in what epigenetic biomarkers will be able to provide to the world.
• Management believes they are well-positioned to help reduce barriers in advancing epigenetic research and the development of epigenetic-based products.
• Management expects that their liquidity requirements will continue to consist of working capital, including payments of outstanding debt and accrued liabilities and general corporate expenses associated with the growth of their business.

Industry Context

The company's move into healthcare with the acquisitions of Myrtle and RCHI reflects a trend of diversification in the healthcare industry. The company's focus on epigenetic biomarkers aligns with the growing interest in personalized medicine and preventative healthcare.

Comparison to Industry Standards

• The company's revenue growth is significant compared to the previous year, but it is still in the early stages of integrating its acquisitions.
• The company's net loss is still substantial, indicating that it needs to improve its profitability.
• The company's cash position is very weak, which is a concern for its ability to continue operations.
• The company's debt levels are high, which could limit its financial flexibility.
• Compared to other companies in the healthcare and biotechnology sectors, FOXO's financial metrics are below average, particularly in terms of profitability and cash reserves. For example, companies like Exact Sciences (EXAS) and Invitae (NVTA) in the genetic testing space, while also facing challenges, have significantly higher revenue and cash reserves. Similarly, hospital operators like HCA Healthcare (HCA) and Tenet Healthcare (THC) have much larger scale and more established revenue streams.

Management Changes

Corporate Governance

Legal Proceedings

• The company is in discussion with Illumina Inc's counsel to settle a summary judgment in the amount of $822,000.
• The company was made aware of a Complaint made by two of the holders of the company's Senior PIK Notes claiming $650,000 and $325,000, respectively.

Related Party Transactions

• The company has entered into various transactions with related parties, including the KR8 Agreement, leases with RHI subsidiaries, and promissory notes with related parties.
• The company's Interim CEO and Interim CFO each are equity owners of KR8.

Stakeholder Impact

• Shareholders face significant risk due to the company's weak financial position and potential delisting from the NYSE American.
• Employees may be affected by potential cost-cutting measures or restructuring.
• Customers may be impacted by changes in service offerings or pricing.
• Creditors face the risk of non-payment due to the company's high debt levels and weak cash position.
• Suppliers may be affected by the company's financial instability and potential inability to pay for goods and services.

Next Steps

• The company will continue ongoing capital raise initiatives.
• The company will pursue additional strategic operating companies.
• The company will commercialize its products to generate revenue.
• The company will seek shareholder approval for the conversion of the Series B Preferred Stock.

Key Dates

Keywords

Healthcare, Epigenetics, Acquisition, Financial Results, Debt, Loss, Revenue, Biomarkers, NYSE American, Going Concern